Ensidipine application methods and dosage guidance

Enasidenib/Idhifa is a targeted therapy for patients with acute myeloid leukemia (AML) who carry IDH2 gene mutations.

Ensidipine is usually given to patients in oral form, with or without food. To ensure optimal results, patients should take ensidipine at the same time every day and avoid missing or taking more than one dose. When taking, swallow ensidipine tablets whole and do not chew or break the tablets.

The recommended dose of ensidipine is100mg (mg) taken orally once daily until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treatment should be continued for at least 6 months.

Generally, the initial dose of ensidipine is100mg taken orally once daily. This dose was determined based on comprehensive consideration of data from multiple clinical trials and patient safety and tolerability.

During treatment, your doctor may make adjustments to the dose of ensidipine based on the patient's response and tolerance. For example, doctors may reduce the dose if the patient experiences severe side effects or cannot tolerate the current dose. Conversely, if a patient responds well to and tolerates the treatment, the doctor may consider increasing the dose to further improve efficacy.

Before using ensidipine, patients need to be tested forIDH2 gene mutations to ensure the effectiveness of the drug. During treatment, patients should undergo regular blood tests and other related monitoring to evaluate the efficacy and safety of the drug. If any discomfort or adverse reactions occur, patients should inform their doctor promptly.

Ensidipine may interact with other drugs. Therefore, before using ensidipine, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and supplements. Physicians can assess potential interaction risks on a case-by-case basis and make adjustments accordingly.

Reference materials:

https://www.drugs.com/mtm/enasidenib.html